Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

ClinicalTrials.gov ID: NCT00468845

Public ClinicalTrials.gov record NCT00468845. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.

Study identification

NCT ID
NCT00468845
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
501 participants

Conditions and interventions

Eligibility (public fields only)

Age range
25 Years to 70 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2007 (Type not available)
Primary completion
May 2010 (Actual)
Completion
Oct 2010 (Actual)
Last update posted
Feb 10, 2021

2007 – 2010

United States locations

U.S. sites
14
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
Pfizer Investigational Site Mobile Alabama 36608 —
Pfizer Investigational Site Glendale Arizona 85308 —
Pfizer Investigational Site Phoenix Arizona 85020 —
Pfizer Investigational Site Phoenix Arizona 85023 —
Pfizer Investigational Site Phoenix Arizona 85027 —
Pfizer Investigational Site Glendale California 91206 —
Pfizer Investigational Site Pasadena California 91105 —
Pfizer Investigational Site Miami Florida 33136-1096 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Philadelphia Pennsylvania 19104 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15213 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15232 —
Pfizer Investigational Site Houston Texas 77024 —
Pfizer Investigational Site Houston Texas 77054 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00468845, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2021 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00468845 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →